Novartis India has acquired Business Standard, the Indian business daily, for an undisclosed amount. The transaction transfers ownership of the publication’s English and Hindi editions, along with its digital platforms, to the pharmaceutical company’s Indian arm. The deal was finalized after a period of negotiation, with terms remaining private between the two parties.
Business Standard operates as a standalone financial newspaper, publishing from twelve centres across India, including New Delhi, Mumbai, Kolkata, and Bengaluru, with additional printing in Bhopal. Its Hindi edition reaches readers from six cities. The publication’s website attracts over 15 million unique visitors monthly, a figure it reports as the highest for any independent business newspaper site in the country. The editorial team, led by Shailesh Dobhal, maintains a focus on accuracy and independent commentary. Novartis India, part of the global healthcare group, is primarily known for its pharmaceutical operations, including research-based medicines and generics.
The rationale for the acquisition lies in Novartis India’s stated interest in expanding its corporate communications and stakeholder engagement capabilities. By owning a media property with a dedicated readership among business professionals, the company gains a direct channel to influence financial discourse and policy discussions. For Business Standard, the deal provides financial backing from a large parent organisation, which could support its digital growth and editorial independence, though the latter will be closely watched given the buyer’s commercial interests in healthcare.
The acquisition is expected to create operational efficiencies in areas such as distribution and administrative support, while the newsroom structure remains intact. No changes to editorial leadership or publication frequency have been announced. The combined entity will operate with Business Standard as a subsidiary, retaining its brand identity under Novartis India’s ownership.
The transaction positions Novartis India with a unique asset in the Indian media landscape, where few pharmaceutical firms hold direct control over news outlets. The coming months will likely reveal how the company balances its corporate objectives with the newspaper’s editorial mandate, and whether the acquisition prompts similar moves by other multinationals seeking media influence in the region.